

Website: jagadishwarpharma.com E_mail ID: jpwltd@yahoo.com Phone no.: +917890587489

Date: 11th July, 2017

To Compliance Department Metropolitan Stock Exchange of India Limited 4th Floor, Vibgyor Towers, Plot No. C 62, G Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098

<u>Sub:</u> <u>Submission of Corporate Governance Report under regulation 27(2)(a) for the quarter ended June 30, 2017</u>

Dear Sir/Madam,

Please find enclosed herewith the Corporate Governance Report for the quarter ended June 30, 2017 under regulation 27(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request to update your records.


Thanking You.

Yours faithfully,

For Jagadish War Pharmaceutical Works Limited

Swapan Sackar (A)
Managing Director
DIN: 05149442

Encl: As above



Website: jagadishwarpharma.com E_mail ID: jpwltd@yahoo.com Phone no.: +917890587489

Format to be submitted by listed entity on quarterly basis

1 Name of Listed Entity: Jagadishwar Pharmaceutical Works Limited

Quarter ending: 30th June, 2017


I. Co	I. Composition of Board of Directors							
Title	Name of	PAN ^{\$} &	Category	Date of	Tenure*	No of	Number of	No of post of
(Mr.	the	DIN	(Chairperson	Appointmen		Directorshi	memberships	Chairperson in
/ Ms)	Director		/Executive/N	t in the		p in listed	in Audit/	Audit/
			on-	current term		entities	Stakeholder	Stakeholder
			Executive/in	/cessation		including	Committee(s)	Committee held
			dependent/N			this listed	including this	in listed entities
			ominee)&			entity	listed entity	including this
						(Refer	(Refer	listed entity
						Regulation	Regulation	(Refer Regulation
						25(1) of	26(1) of	26(1) of Listing
						Listing	Listing	Regulations)
						Regulations)	Regulations)	
Mr.	Swapan Sarkar	BSCPS 6769R & 051494 42	Executive/ Non- Independe nt	21.05.2012	N.A.	8	3	
Mr.	Partha Chakra borty	AGSPC 2105N & 019955 91	Non- Executive/ Independe nt	01.08.2015	N.A.	8	3	2
Smt	Kakali Ghosh	BPZPG 8544J & 07188585	Non- Executive/ Independen t	01.08.2015	N.A.	8	3	1

^{\$}PAN number of any director would not be displayed on the website of Stock Exchange

^{*} to be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period.

II. Composition of Committees		
Name of Committee	Name of Committee members	Category
		(Chairperson/Executive/Non-
		Executive/independent/Nomi
		nee)\$
1. Audit Committee	Mr. Swapan Sarkar	Member/ Executive/ Non-
		independent
	Mr. Partha Chakraborty	Chairman / Non-Executive/
		Independent
	Smt. Kakali Ghosh	Member/ Non-
		Executive/Independent
2. Nomination & Remuneration	Mr. Swapan Sarkar	Member/ Executive/ Non-
Committee		independent
	Mr. Partha Chakraborty	Chairman/ Non-Executive/

[&]amp;Category of directors means executive/non-executive/independent/Nominee. if a director fits into more than one category write all categories separating them with hyphen



Website: jagadishwarpharma.com E_mail ID: jpwltd@yahoo.com Phone no.: +917890587489

CIN: L24232AS1987PLC002803

		Independent		
	Smt. Kakali Ghosh	Member/ Non-		
		Executive/Independent		
3. Risk Management Committee(if	Not Applicable	Not Applicable		
applicable)				
4. Stakeholders Relationship	Mr. Swapan Sarkar	Member/ Executive/ Non-		
Committee'		independent		
	Mr. Partha Chakraborty	Member/ Non-Executive/		
		Independent		
	Smt. Kakali Ghosh	Chairman/ Non-		
		Executive/Independent		
*Category of directors means executive/non-executive/independent/Nominee. if a director fits into				
more than one category write all categories separating them with hyphen				
III Mosting of Board of Directors				

III. Meeting of Board of Directors

Date(s) of Meeting (if any) in	Date(s) of Meeting (if any) in the	Maximum gap between any two
the previous quarter	relevant quarter	consecutive (in number of days)
09.02.2017	29.05.2017	110 days

IV. Meeting of Committees

8					
	Date(s) of meeting of	Whether requirement	Date(s) of meeting of the	Maximum gap between	
	the committee in the	of Quorum met	committee in the	any two consecutive	
	relevant quarter	(details)	previous quarter	meetings in number of	
				days*	
	29.05.2017	Yes	09.02.2017	110 days	

^{*}This information has to be mandatorily be given for audit committee, for rest of the committees giving this information is optional

V. Related Party Transactions

Subject	Compliance status (Yes/No/NA) ^{refer note below}		
Whether prior approval of audit committee obtained	N/A		
Whether shareholder approval obtained for material RPT	N/A		
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	N/A		

Note

IIn the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A.. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2 If status is "No" details of non-compliance may be given here.

VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & remuneration committee



Website: jagadishwarpharma.com E_mail ID: jpwltd@yahoo.com Phone no.: +917890587489

CIN: L24232AS1987PLC002803

- c. Stakeholders relationship committee
- d. Risk management committee (applicable to the top 100 listed entities)
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:

For Jagadishwar Pharmaceutical Works Limited

Swapan Sickar & Managing Director DIN: 05149442

Note:

Information at Table I and II above need to be necessarily given in 1st quarter of each financial year. However if there is no change of information in subsequent quarter(s) of that financial year, this information may not be given by Listed entity and instead a statement "same as previous quarter" may be given.